Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
53 hedge funds and large institutions have $342M invested in Mersana Therapeutics in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 14 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
16% more capital invested
Capital invested by funds: $295M → $342M (+$46.3M)
0.05% more ownership
Funds ownership: 3.29% → 3.34% (+0.05%)
5% less funds holding
Funds holding: 56 → 53 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$5.65M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.59M |
| 3 |
BlackRock
New York
|
+$3.31M |
| 4 |
Millennium Management
New York
|
+$2.16M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.27M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.99M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$2.08M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$568K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$495K |
MRSN Hedge Fund Activity: Q2 2018 in Review
53 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2018, worth a combined $342M — up 16% from $295M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MRSN and 11 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 20 added.
The largest buyer was Ghost Tree Capital, adding an estimated $5.65M. The largest seller was Rock Springs Capital Management, cutting an estimated $5.27M.
- 53 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2018, down from 56 in Q1 2018.
- Funds reported $342M of Mersana Therapeutics stock for Q2 2018, up 16% quarter-over-quarter.
- 11 funds opened new Mersana Therapeutics positions in Q2 2018 and 14 closed out, a net change of -3 holders.
- The largest Mersana Therapeutics buyer in Q2 2018 was Ghost Tree Capital, an estimated $5.65M added.
- The largest Mersana Therapeutics seller in Q2 2018 was Rock Springs Capital Management, an estimated $5.27M sold.
Based on aggregated 13F filings for Q2 2018.